Novartis’ chronic heart failure treatment ‘Entresto’ is growing rapidly. Its quarterly sales first exceeded KRW 10 billion in 5 years since its release in Q3 this year.

The analysis is that its rapid growth was due to its de facto domination of the market.

However, with the nearing entry of ▲SGLT-2 class diabetes treatments, ▲new chronic heart failure treatments, ▲Entresto generics, various prospects are being raised on whether Entresto will be able to maintain its growth rate.

◆Quarterly prescriptions of Entresto exceed KRW 10 billion…2.6 time growth in 3 years

According to the market research institution UBIST on the 12th, Entresto’s Q3 pres